Mounjaro to Be Covered by Gesy for Diabetes and Adult Obesity
6 Articles
6 Articles
Mounjaro to be covered by Gesy for diabetes and adult obesity
The anti-obesity drug Mounjaro will be covered by Gesy for Type II diabetes and obesity in adults from Thursday, the health insurance organisation has announced. Coverage of tirzepatide, the drug’s active ingredient, will be subject to approved protocols. The revised protocol for Ozempic (semaglutide) for Type II diabetes will also take effect, with Ozempic designated […]
They are presented as the miracle drugs of weight loss. For the past two years, Ozempic, Wegovy and Mounjaro have established themselves as the flagship products of pharmacies. It's a great pleasure to... Read more Health: all about the "miracle drugs" anti-obesity reimbursed by the Social Security has appeared first on Current Values.
The inclusion of the pharmaceutical product Mounjaro in the General Health Insurance System for the indications of type II diabetes mellitus and obesity in adults, was announced by the Health Insurance Organization. The Health Insurance Organization states, in its announcement, that from October 15, 2026, the administration of the pharmaceutical product tirzepatide (Mounjaro) will be reimbursed for the indications of type II diabetes mellitus [……
Munjaro Against Obesity Enters the Greek National Health Insurance System – What Changes for Ozempic
The well-known injectable drug for the treatment of type 2 diabetes and obesity, Munjaro, is included in the General Health System (GHS), with its administration being based on specific criteria and protocols. As he explained, this particular drug has an indication for both patients with type 2 diabetes and patients with obesity, unlike Ozempic, which within the framework of the GHS is administered exclusively for type 2 diabetes. He emphasized …
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
